Abstract
BackgroundWe explored the ideal method of establishing subcutaneous, breast, and liver tumor models using the same Walker-256 cells, and investigated the dynamic growth characteristics using 18F-deoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), which provides basic information for choosing an experimental animal model.Material/MethodsWe established tumor models in 3 locations (subcutaneous, breast, and liver) in W256 Sprague-Dawley rats. 18F-FDG PET/CT imaging was performed from 6 days to 18 days after injecting the cells subcutaneously. Tumor volume of interest (VOI), maximum standard uptake value (SUVmax), and average standard uptake value (SUVavg) were obtained from the image. The difference of the growth characteristics in tumor volume and SUVs among the 3 groups were compared. Histopathology of the tumors was also analyzed.ResultsThe tumors in subcutaneous location grew fastest, followed by tumors located in the breast, and tumors in the liver grew slowest. Significant differences in tumor VOI (p=0.01) were observed. 18F-FDG uptake of the subcutaneous and breast tumors increased until day 10 and then decreased subsequently. 18F-FDG uptake of the liver tumor reached a peak at day 10, and necrosis peaked at day 12. The histopathology analysis results indicated that the necrosis was mainly located in the center of tumors while the viable tissues were located on the periphery. Similarly, CD 31 and Ki-67 were mainly expressed on the tumor periphery.ConclusionsSubcutaneous, breast, and liver tumor models were easy to establish using Walker-256 cells. They showed fast growth and high uptake of 18F-FDG. These kinds of tumor models were optimal in evaluating anti-tumor efficacy by 18F-FDG PET/CT, but it may be essential to determine the best time-points at which to use it.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Medical science monitor : international medical journal of experimental and clinical research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.